Covis Announces Successful Completion of Its Previously Announced Financial Recapitalization Transaction, Resulting in a Material Strengthening of Its Financial Position
June 01, 2023 06:30 ET
|
Covis Pharma
Transaction supported by 100% of First Lien and 100% of Second Lien Lenders Results in material strengthening of the Company’s balance sheet and liquidity profile Existing Equity Sponsors remain the...
Covis Statement on FDA Decision to Withdraw Approval of Makena®
April 07, 2023 08:15 ET
|
Covis Pharma
ZUG, Switzerland, April 07, 2023 (GLOBE NEWSWIRE) -- Following the U.S. Food and Drug Administration’s decision, Covis Pharma Group (“Covis”) is effectuating the withdrawal of Makena®...
Covis Announces Signing of Support Agreements With Its Lenders and Equity Sponsors, Leading to a Material Strengthening of Its Financial Position, Including the Elimination of ~$450 Million of Debt
April 03, 2023 07:00 ET
|
Covis Pharma
Support Agreement signed by approximately 95% of First Lien Lenders and 100% of Second Lien Lenders These actions will significantly improve the Company’s balance sheet as well as liquidity Equity...
Covis Pharma Responds to Presiding Officer’s Report Summarizing FDA Advisory Committee Hearing
March 07, 2023 17:56 ET
|
Covis Pharma
Company Has Requested an Orderly Wind-down in Effort to Voluntarily Withdraw Makena® ZUG, Switzerland, March 07, 2023 (GLOBE NEWSWIRE) -- Covis Pharma Group (“Covis”), today announced it has...
Covis Pharma Announces Positive Topline Results from the AVANT Phase 3 Clinical Trial Showing Significant Improvement in Patients with Moderate to Severe Stable COPD
October 25, 2022 13:41 ET
|
Covis Pharma
ZUG, Switzerland, Oct. 25, 2022 (GLOBE NEWSWIRE) -- Covis Pharma Group (“Covis”), a global specialty pharmaceutical company that markets therapeutic solutions for patients with life-threatening...
Covis Pharma Reports on FDA Advisory Committee Hearing for Makena®
October 19, 2022 15:58 ET
|
Covis Pharma
ZUG, Switzerland, Oct. 19, 2022 (GLOBE NEWSWIRE) -- Covis Pharma Group (the “Company”), today reported that the Obstetrics, Reproductive, and Urologic Drugs Advisory Committee to the U.S. Food and...
Covis Pharma Group Announces Executive Leadership Appointment in Canada
July 14, 2022 11:00 ET
|
Covis Pharma
ZUG, Switzerland, July 14, 2022 (GLOBE NEWSWIRE) -- Covis Pharma Group (the “Company”), a global specialty pharmaceutical company that markets therapeutic solutions for patients with...
Covis Pharma Provides Update on FDA Public Hearing for Makena®
June 14, 2022 16:00 ET
|
Covis Pharma
ZUG, Switzerland, June 14, 2022 (GLOBE NEWSWIRE) -- Covis Pharma GmbH, an affiliate of Group S.à r.l. (collectively, “Covis”), announced today that the U.S. Food & Drug Administration (FDA)...
Covis Pharma-Gruppe gibt zwei Ernennungen im leitenden Managementteam bekannt
February 01, 2022 10:15 ET
|
Covis Pharma
- Michelle Lock kommt als Chief Operating Officer zu Covis Pharma.- Das Unternehmen gibt mit der Ernennung von Sandy Loreaux zum President, U.S. Business, außerdem einen Wechsel der Führungsspitze...
Covis Pharma Group annonce deux nominations au sein de son équipe de direction
February 01, 2022 10:15 ET
|
Covis Pharma
- Michelle Lock rejoint Covis Pharma en tant que directrice de l'exploitation.- La Société annonce également la transition du leadership exécutif avec la nomination de Sandy Loreaux au poste de...